Phase I clinical study combining L19-IL2 with stereotactic ablative body radiotherapy in patients with oligometastatic solid tumor


Protocolnummer:
NCT02086721

Ziekenhuizen:
Maastricht UMC+
Maastro Clinic

Titel:
Phase I clinical study combining L19-IL2 with stereotactic ablative body radiotherapy in patients with oligometastatic solid tumor

  • To determine the safety and efficacy of L19-IL2 combined with SABR in patients with an oligometastatic solid tumor (renal cell carcinoma; melanoma)
  • Stadium: advanced, oligometastatic

Behandeling:
Stereotactic radiotherapy and L19-IL2

Stadium:

Belangrijkste in/exclusiecriteria:

Inclusie criteria:

  • Patients (men or women) with histologically proven renal cell cancer who are starting treatment with sunitinib
  • > 18 years
  • Hb >5.6 mmol/L

Exclusie criteria:

  • Patients with known genetic abnormalities affecting platelet function and coagulation
  • Patients who received anti-platelet medication during the study or 14 days before the onset of the study
  • Patients who have received blood or platelet transfusion during the study or 14 days before the onset of the study
  • Patients who have a diagnosed active infection, ulcers and/or non-healing wounds.
  • Patients who are pregnant or breastfeeding
  • Active thrombosis

Contactpersoon:
Maureen J. Aarts, MD, PhD: mjb.essers.aarts@mumc.nl
Ann Hoeben, MD, PhDl: ann.hoeben@mumc.nl

Alle niercelcarcinoom trials